King H, Lewin S
Immunol Rev. 2024; 328(1):350-371.
PMID: 39248154
PMC: 11659942.
DOI: 10.1111/imr.13388.
Lokhande L, Nilsson D, de Matos Rodrigues J, Hassan M, Olsson L, Pyl P
Cancers (Basel). 2024; 16(13).
PMID: 39001353
PMC: 11240320.
DOI: 10.3390/cancers16132289.
Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M
Am J Cancer Res. 2024; 14(4):1634-1648.
PMID: 38726288
PMC: 11076267.
DOI: 10.62347/ECED5481.
Ma Y, Shi R, Li F, Chang H
Cell Commun Signal. 2024; 22(1):262.
PMID: 38715122
PMC: 11075321.
DOI: 10.1186/s12964-024-01641-7.
Wang C, Biswas P, Islam A, Chen M, Chueh P
Cells. 2024; 13(5.
PMID: 38474377
PMC: 10930979.
DOI: 10.3390/cells13050413.
TCR-like antibody and GITR signaling lead to effective CAR-T against solid tumor.
Gascoigne N
Mol Ther. 2024; 32(3):569-571.
PMID: 38382528
PMC: 10928281.
DOI: 10.1016/j.ymthe.2024.02.014.
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4/HLA-A∗02:01 complex.
Wang L, Matsumoto M, Akahori Y, Seo N, Shirakura K, Kato T
Mol Ther. 2024; 32(3):734-748.
PMID: 38243600
PMC: 10928314.
DOI: 10.1016/j.ymthe.2024.01.018.
Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes.
Nagai H, Azuma M, Sato A, Shibui N, Ogawara S, Tsutsui Y
Cells. 2023; 12(12).
PMID: 37371066
PMC: 10297085.
DOI: 10.3390/cells12121596.
Targeting GITR in cancer immunotherapy - there is no perfect knowledge.
Davar D, Zappasodi R
Oncotarget. 2023; 14:614-621.
PMID: 37335294
PMC: 10278658.
DOI: 10.18632/oncotarget.28461.
Multi-omic analysis of the cardiac cellulome defines a vascular contribution to cardiac diastolic dysfunction in obese female mice.
Dona M, Hsu I, Meuth A, Brown S, Bailey C, Aragonez C
Basic Res Cardiol. 2023; 118(1):11.
PMID: 36988733
PMC: 10060343.
DOI: 10.1007/s00395-023-00983-6.
Predictive biomarkers for the responsiveness of recurrent glioblastomas to activated killer cell immunotherapy.
Hwang S, Lim J, Kang H, Jeong J, Joung J, Heo J
Cell Biosci. 2023; 13(1):17.
PMID: 36694264
PMC: 9875464.
DOI: 10.1186/s13578-023-00961-4.
High-level of intratumoral GITR+ CD4 T cells associate with poor prognosis in gastric cancer.
Ke S, Xie F, Guo Y, Chen J, Wang Z, Yu Y
iScience. 2022; 25(12):105529.
PMID: 36419848
PMC: 9676631.
DOI: 10.1016/j.isci.2022.105529.
Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.
Santiago-Sanchez G, Hodge J, Fabian K
Front Immunol. 2022; 13:993624.
PMID: 36159809
PMC: 9492957.
DOI: 10.3389/fimmu.2022.993624.
Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics.
Dwivedi M, Tiwari S, Kemp E, Begum R
Heliyon. 2022; 8(8):e10450.
PMID: 36082331
PMC: 9445387.
DOI: 10.1016/j.heliyon.2022.e10450.
Combinations of anti-GITR antibody and CD28 superagonist induce permanent allograft acceptance by generating type 1 regulatory T cells.
Que W, Ma K, Hu X, Guo W, Li X
Sci Adv. 2022; 8(31):eabo4413.
PMID: 35921418
PMC: 9348800.
DOI: 10.1126/sciadv.abo4413.
Antibody-Targeted TNFRSF Activation for Cancer Immunotherapy: The Role of FcγRIIB Cross-Linking.
Liu L, Wu Y, Ye K, Cai M, Zhuang G, Wang J
Front Pharmacol. 2022; 13:924197.
PMID: 35865955
PMC: 9295861.
DOI: 10.3389/fphar.2022.924197.
Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity.
Liu H, Wu W, Sun G, Chia T, Cao L, Liu X
Cell Rep Med. 2022; 3(6):100660.
PMID: 35732156
PMC: 9245059.
DOI: 10.1016/j.xcrm.2022.100660.
Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma.
Tang X, Yang Z, Kim H, Anagnostou T, Yu Y, Wu X
Clin Cancer Res. 2022; 28(19):4322-4335.
PMID: 35686915
PMC: 10443733.
DOI: 10.1158/1078-0432.CCR-22-0977.
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Davar D, Zappasodi R, Wang H, Naik G, Sato T, Bauer T
Clin Cancer Res. 2022; 28(18):3990-4002.
PMID: 35499569
PMC: 9475244.
DOI: 10.1158/1078-0432.CCR-22-0339.
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism.
He C, Maniyar R, Avraham Y, Zappasodi R, Rusinova R, Newman W
Sci Adv. 2022; 8(8):eabm4552.
PMID: 35213218
PMC: 8880771.
DOI: 10.1126/sciadv.abm4552.